Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29552312
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29552312
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Oncotarget
2018 ; 9
(15
): 12316-12322
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Precision oncology in advanced cancer patients improves overall survival with
lower weekly healthcare costs
#MMPMID29552312
Haslem DS
; Chakravarty I
; Fulde G
; Gilbert H
; Tudor BP
; Lin K
; Ford JM
; Nadauld LD
Oncotarget
2018[Feb]; 9
(15
): 12316-12322
PMID29552312
show ga
The impact of precision oncology on guiding treatment decisions of late-stage
cancer patients was previously studied in a retrospective analysis. However, the
overall survival and costs were not previously evaluated. We report the overall
survival and healthcare costs associated with precision oncology in these
patients with advanced cancer. Building on a matched cohort study of 44 patients
with metastatic cancer who received all of their care within a single
institution, we evaluated the overall survival and healthcare costs for each
patient. We analyzed the outcomes of 22 patients who received genomic testing and
targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015,
and compared to 22 historically controlled patients (control) who received
standard chemotherapy (N = 17) or best supportive care (N = 5). The median
overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks
for the control group (P = 0.008) when matching on age, gender, histological
diagnosis and previous treatment lines. Average costs over the entire period were
$2,720 per week for the targeted treatment group and $3,453 per week for the
control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage
cancer diagnoses found that those who received a targeted cancer treatment (N =
93) had 6.9% lower costs in the last 3 months of life compared with those who did
not. These findings suggest that precision oncology may improve overall survival
for refractory cancer patients while lowering average per-week healthcare costs,
resource utilization and end-of-life costs.
free
free
free
